Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers D > Headlines for Dynavax Technologies Corp. > News item |
Dynavax kept by JMP at market outperform
Dynavax Technologies Corp. was maintained by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $9 per share following a conference call conducted by the firm with hepatitis B virus clinician and researcher Dr. Scott Halperin, who expressed high enthusiasm for Dynavax's HBV-ISS vaccine from a clinical development plan and technological perspective. Dynavax shares Thursday were up $0.16, or 2.39%, at $6.86 on volume of 24,399 shares versus the three-month running average of 35,996.9 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.